Atrial fibrillation and the use of warfarin in patients admitted to an acute stroke unit

Canadian Journal of Cardiology

Volumn 16, Issue 4, 2000, Pages 481-485

  Leckey, Richard ^a,b   Aguilar, Eslier G ^b   Phillips, Stephen J ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Anticoagulants; Atrial fibrillation; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; TICLOPIDINE; WARFARIN;

ADULT; BRAIN HEMORRHAGE; CONFERENCE PAPER; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HEAT STROKE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; SINUS RHYTHM; SURVIVAL RATE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; FEMALE; HOSPITAL MORTALITY; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; PROSPECTIVE STUDIES; REGISTRIES; WARFARIN;

EID: 0034012452     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Phillips SJ, Whisnant JP, O'Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990;65:344-59.
2. Whisnant JP, Wiebers DO, O'Fallon WM, Sicks JD, Frye RL. A population-based model of risk factors for ischemic stroke: Rochester, Minnesota. Neurology 1996;47:1420-8.
3. Laupacis A, Cuddy TE. Prognosis of individuals with atrial fibrillation. Can J Cardiol 1996;12(Suppl A)14A-6A.
4. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
5. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
6. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cetebral ischemia. N Engl J Med 1995;333:5-10.
7. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 1998;114(5 Suppl):579S-89S.
8. Connolly SJ, Turpie AGG. Antithrombotic therapy in atrial fibrillation. Can J Cardiol 1996;12(Suppl A):17A-20A.
9. Dean AG, Dean JA, Burton AH, Dicker RC. Epi Info: A general-purpose microcomputer program for public health information systems. Am J Prev Med 1991;7:178-82.
10. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-6.
11. Broderick JP, Phillips SJ, O'Fallon WM, Frye RL, Whisnant JP. Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. Stroke 1992;23:1250-6.
12. Sandercock P, Bamford J, Dennis M, Burn J, Slattery J, Jones L, Boonyakarnkul S, Warlow C. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long-term prognosis. BMJ 1992;305:1460-5.
13. Lin H-J, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-4.
14. Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996;27:1765-9.
15. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81.
16. Bath PMW, Prasad A, Brown MM, MacGregor GA. Survey of use of anticoagulation in patients with atrial fibrillation. BMJ 1993;307:1045.
17. Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 1996;11:713-20.
18. Laupacis A, Sullivan K, and the Canadian Atrial Fibrillation Anticoagulation Study Group. Canadian Atrial Fibrillation Anticoagulation Study: Were the patients subsequently treated with warfarin? CMAJ 1996;154:1669-74.
19. The Clinical Quality Improvement Network (CQIN) Investigators. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. Can J Cardiol 1998;14:695-702.
20. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998;97:1231-3.
21. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998;352:1167-71.
22. Beyth RJ, Antani MR, Covinsky KE, et al. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med 1996;11:721-8.
23. Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991;151:1950-3.
24. Lancaster TR, Singer DE, Sheehan MA, et al, for the Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Arch Intern Med 1991;151:1944-9.
25. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
26. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-91.
27. English KM, Channer KS. Managing atrial fibrillation in elderly people. BMJ 1999;318:1088-9.
28. Lomas J, Enkin M, Anderson GN, Hannah WJ, Vayda E, Singer J. Opinion leaders vs audit and feedback to implement practice guidelines. Delivery after previous cesarean section. JAMA 1991;265:2202-7.
29. Grimshaw JM, Russell IT. Achieving health gain through clinical guidelines II: ensuring guidelines change medical practice. Qual Health Care 1994;3:45-52.
30. Thomson R, Lavender M, Madhok R. How to ensure that guidelines are effective. BMJ 1995;311:237-42.